Watch and Wait strategy in rectal cancer: when surgery can be avoided
The Watch and Wait strategy (active surveillance) is one of the most important recent developments in rectal cancer treatment. In patients who achieve a complete clinical response after chemoradiotherapy — meaning the tumor disappears completely — surgery can be avoided, keeping the rectum intact. This approach offers a chance at organ preservation without compromising oncological safety.
What complete clinical response means
After neoadjuvant chemoradiotherapy, in approximately 15-25% of patients, the tumor disappears completely. This complete response is assessed by:
- Clinical examination (digital rectal exam) — the tumor is no longer palpable
- Rectoscopy — the rectal mucosa looks normal or has only a flat, white scar
- Pelvic MRI — no visible tumor signal remains
When all these criteria are met, the patient is a candidate for the Watch and Wait strategy.
Who can benefit
Eligibility criteria
- Complete clinical response documented by clinical exam, rectoscopy and MRI
- Informed and motivated patient — understanding the risks and the need for strict monitoring
- Access to a center with experience in this strategy
- No suspicious lymph nodes on restaging MRI
Who is not a candidate
- Patients with partial response (tumor shrunk but did not disappear)
- Patients who cannot follow the strict monitoring program
- Tumors with high-risk factors (vascular invasion, poor differentiation)
The monitoring program
Watch and Wait does not mean “we wait and do nothing.” It means intensive monitoring following a strict protocol:
First 2 years (highest recurrence risk)
- Clinical exam + rectoscopy: every 2-3 months
- Pelvic MRI: every 3-6 months
- Chest-abdomen CT: every 6 months
- CEA (tumor marker): every 3 months
Years 3-5
- Clinical exam + rectoscopy: every 6 months
- Pelvic MRI: every 6-12 months
- Chest-abdomen CT: annually
- Colonoscopy: annually or every 2 years
After 5 years
- 12-month monitoring (per the standard post-rectal-cancer protocol)
What happens if the tumor returns
Approximately 25-30% of patients in Watch and Wait will have a local regrowth of the tumor, usually in the first 2 years. This is NOT a recurrence in the classic sense — it is a regrowth of the primary tumor.
The good news
- Over 95% of regrowths are detected on time through monitoring
- Salvage surgery (TME) has the same oncological outcomes as primary surgery
- Patients operated after regrowth have the same survival as those operated initially
- No chance is lost by trying Watch and Wait
Advantages of Watch and Wait
- Avoiding surgery — with all its risks and consequences
- Preserving bowel function — no LARS syndrome
- No stoma (neither temporary nor permanent)
- Preserving sexual and urinary function
- Better quality of life — studies show significantly higher scores
- Immediate recovery — no surgical convalescence
Risks and limitations
- Anxiety of monitoring — frequent visits and waiting for results can cause stress
- Risk of regrowth — 25-30% of patients will still need surgery
- Limited very-long-term data — the strategy is relatively new (first series from 2004)
- Requires an experienced center — not all hospitals offer this option
Frequently asked questions
Is it a safe strategy?
Yes. Data from over 2,000 patients in international studies show that 5-year survival is equivalent to that of operated patients. The OPRA trial (2023) confirmed the safety of this approach.
If the tumor comes back, have I lost precious time?
No. Intensive monitoring detects regrowth at very early stages. Salvage surgery is performed without delay and has the same outcomes as primary surgery.
Can Watch and Wait be done in stage III?
The strategy is being studied in more advanced stages, especially after total neoadjuvant therapy (TNT). Preliminary results are promising but require further validation.
How long does monitoring last?
For life, with decreasing intensity. In the first 2 years, visits are frequent (every 2-3 months), then become progressively rarer.
How to discuss with your doctor
If you have finished chemoradiotherapy and your doctor mentions a “good response” or “complete response”, ask:
- “Am I a candidate for the Watch and Wait strategy?”
- “How complete is my response to treatment?”
- “What does the restaging MRI show?”
- “Do you have experience with this strategy?”
- “What is the monitoring protocol you propose?”
This article is for informational purposes only and does not replace medical consultation. The decision to follow the Watch and Wait strategy should be made together with an experienced medical team.